High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

Area of Science:

• Oncology
• Radiation Oncology
• Gynecologic Oncology

Background:

• Advanced cervical carcinoma often presents challenges for optimal radiation dose distribution with standard intracavitary techniques.
• High-dose-rate interstitial brachytherapy (HDR-ISBT) offers an alternative approach for delivering precise radiation doses.
• Evaluating HDR-ISBT outcomes is crucial for improving treatment strategies in advanced cervical cancer.

Purpose of the Study:

• To assess the efficacy and safety of high-dose-rate interstitial brachytherapy (HDR-ISBT) in patients with advanced cervical carcinoma.
• To determine if HDR-ISBT can overcome suboptimal dose distributions associated with intracavitary radiation therapy.
• To evaluate survival rates and local control in this patient cohort.

Main Methods:

• A cohort of 25 patients with advanced cervical carcinoma (Stages I-IVA) were treated between 1995 and 2005.
• Treatment involved external beam radiation therapy followed by high-dose-rate interstitial brachytherapy (HDR-ISBT).
• Patients received whole pelvic irradiation, HDR-ISBT, and additional pelvic external beam radiation therapy with a midline block.

Main Results:

• The 5-year progression-free survival and overall survival rates for all patients were 42% and 54%, respectively.
• For Stage III patients, 5-year local control and overall survival rates were 73% and 51%.
• Late toxicities of Grade 3 were observed in 8% of patients.

Conclusions:

• High-dose-rate interstitial brachytherapy (HDR-ISBT) achieved a high rate of pelvic control and survival in advanced cervical cancer.
• The treatment demonstrated an acceptable level of late toxicities.
• HDR-ISBT is a viable option for advanced cervical carcinoma when intracavitary therapy may be suboptimal.